palliative care specialists have expertise in negotiating ACP, access to specialty palliative care is limited, particularly at community cancer centers that are geographically distant from larger academic facilities. 16 The CONNECT study addressed this
Search Results
Michael G. Cohen, Andrew D. Althouse, Robert M. Arnold, Douglas White, Edward Chu, Margaret Rosenzweig, Kenneth J. Smith, and Yael Schenker
Sharyn F. Worrall, Andrea J. Dwyer, Reese M. Garcia, Keavy E. McAbee, and Anjelica Q. Davis
, these unmet needs must be identified and prioritized within the CRC population. Although efforts to improve the patient and survivor experience have gained momentum over the past decade, it is essential to ensure that the CRC community has their needs
Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson, and Yi-Jen Chen
(OR, 1.68; 95% CI, 1.43–1.99; P <.001), Charlson-Deyo comorbidity score ≥2 (OR, 1.46; 95% CI, 1.18–1.81; P <.001), treatment at community facility rather than academic (OR, 1.27; 95% CI, 1.07–1.51; P =.006), and T2 disease compared with the
Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff
RCC in community practice were examined, focusing on systemic therapy. Patients and Methods Data Source and Study Sample NCI Patterns of Care Data: The NCI SEER program collects information on all cancer diagnoses in defined geographic
Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta
. Methods We identified 184 cases of primary adult HNSCC treated at an urban, community-based academic health center between March 1, 2005, and March 8, 2017. The study protocol was approved by the Institutional Review Board (IRB 2018-9739). Patients with
Judy Perotti, Elda Railey, Mary Lou Smith, and Cheya Pope
Peter R. Carroll and Andrew J. Vickers
Few clinical issues have polarized the oncology community as much as screening for prostate cancer, with advocates of prostate-specific antigen (PSA) testing vocal on one side and skeptics just as vocal on the other. At the NCCN 19th Annual Conference, Dr. Peter R. Carroll and Dr. Andrew J. Vickers tackled the controversy surrounding early detection of prostate cancer, focusing attention on the randomized trial results at the heart of the matter; over-detection (the Achilles’ heel of screening); and the rationale behind the new, streamlined 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection, which emphasize selective early detection and treatment and are tightly aligned with the NCCN Guidelines for Prostate Cancer.
